Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06492174 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
A Phase 3 study of In-Stent Restenosis, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 11
- Study locations
NCT06492174 is a Phase 3 study of In-Stent Restenosis that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 20 participants. The trial reports 11 study locations across 10 states.
The verdict
NCT06492174, a Phase 3 study of In-Stent Restenosis, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in diameter.
Conditions Studied
Interventions
- DEVICE AGENT DCB 40 mm
Study Locations (11)
New York
- Columbia University Medical Center - New York
- St. Francis Hospital - Roslyn
Arizona
- Carondelet Medical Group St. Mary's Hospital - Tucson
California
- Cedars Sinai Medical Center - Los Angeles
Georgia
- Emory University Hospital - Atlanta
Michigan
- Henry Ford Hospital - Detroit
Ohio
- Lindner Center for Research and Education at Christ Hospital - Cincinnati
Pennsylvania
- UPMC Pinnacle Health - Wormleysburg
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06492174
The ClinicalTrials.gov registry entry for NCT06492174 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with In-Stent Restenosis appearing as the primary indexed condition, and to 1 intervention - of which AGENT DCB 40 mm is the first listed.
NCT06492174 reports 11 study locations spanning 10 distinct geographic areas - top geographies include New York, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06492174 about?
NCT06492174 is a clinical study titled "A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort". The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length (by visual estimate) in a native coronary artery 2.0 mm to 4.0 mm in di...
What is the current status of trial NCT06492174?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2024-10-07. Estimated completion is 2027-12.
What conditions does trial NCT06492174 study?
This clinical trial studies the following conditions: In-Stent Restenosis.
What interventions are being tested in trial NCT06492174?
The interventions under investigation include: AGENT DCB 40 mm (DEVICE).
Who is sponsoring clinical trial NCT06492174?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06492174 being conducted?
This trial has 11 study locations across Arizona, California, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for In-Stent Restenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.